AKT1 and endometrial carcinoma: The remaining patient in PR had dual mutations in AKT and mTOR; this patient with endometrial carcinoma (and dual AKT E17K and mTOR mutation A1459D) remains on treatment (currently on 26 months of treatment), in ongoing PR.